ProKidney Corp. Class A Ordinary Shares (PROK)
Stock · NASDAQ · Health Care
$1.33as of 10/16/2026
Price chart
Active signals
PROK Signal Track Record
How signals performed across all stocks →What PROK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -7.2% | 37% | September 16, 2026 |
| Bollinger Band BreakdownActive now | 24 | +6.6% | 58% | September 23, 2026 |
| Bollinger Band Breakout | 19 | -14.8% | 32% | June 30, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +4.5% | 60% | March 6, 2026 |
| Any 20-session window (baseline) | -4.0% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PROK
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserv…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 231
- Website
- prokidney.com/
Fundamentals
- 1-day range
- $1.31$1.47
- Market cap
- $495.38M
- P/E (trailing)
- —
- P/E (forward)
- -2.27
- EPS (trailing)
- $-0.55
- Dividend yield
- —
- Beta
- 1.95
- Avg. volume
- 1.30M
How ProKidney Corp. Class A Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
ProKidney Corp. Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PROKProKidney Corp. Class A Ordinary Shares$1.33▼ 8.59%Market cap $495.38MP/E —$1.3$3.48
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
- VALNValneva SE American Depositary Shares$5.61▼ 5.08%Market cap $491.51MP/E —$2.03$5.15
- KYTXKyverna Therapeutics Inc. Common Stock$5.67▼ 5.03%Market cap $471.16MP/E —$5.61$13.67
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.33 | ▼ 8.59% | $1.3$3.48 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
| VALN Valneva SE American Depositary Shares | $491.51M | — | $5.61 | ▼ 5.08% | $2.03$5.15 |
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $5.67 | ▼ 5.03% | $5.61$13.67 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Brian JG Pereira · August 20, 2026 · Sale27.1K @ $1.42
- Brian JG Pereira · August 20, 2026 · Sale222.9K @ $1.42
- Brian JG Pereira · August 19, 2026 · Sale27.1K @ $1.44
- Brian JG Pereira · August 19, 2026 · Sale222.9K @ $1.44
- Brian JG Pereira · August 18, 2026 · Sale27.8K @ $1.37
- Brian JG Pereira · August 18, 2026 · Sale229.3K @ $1.37
- Brian JG Pereira · August 4, 2026 · Conversion675.2K
- Brian JG Pereira · August 4, 2026 · Conversion81.9K
- Locke Kenneth Thomas · July 1, 2026 · Grant750.0K
- Todd C. Girolamo · June 12, 2026 · Conversion163.9K
- Brian JG Pereira · May 28, 2026 · Grant135.0K
- DOYLE WILLIAM F · May 28, 2026 · Grant135.0K
- Jimenez Santos Jose Ignacio · May 28, 2026 · Grant135.0K
- Fox Jennifer A. · May 28, 2026 · Grant135.0K
- Sinha Uma · May 28, 2026 · Grant135.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 41.90M
- Total value held
- $74.42M
- Institutional holders
- 66
- Unknown12.34M
- Unknown8.96M
- Unknown2.27M
- Unknown2.00M
- Unknown1.81M
- Unknown1.61M
- Unknown1.39M
- Unknown1.25M
- Unknown1.23M
- Unknown1.15M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026
ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026. ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.